Press Release

Mitsubishi Tanabe Pharma America Announces ALS Presentations at American Academy of Neurology Annual Meeting

Analysis of Patient U.S. Health Claims Data of 170 Million Individuals
Identifies Potential Early Signals of ALS

JERSEY CITY, N.J., April 18, 2018 – Mitsubishi Tanabe Pharma America, Inc. (MTPA) today announced presentations on amyotrophic lateral sclerosis (ALS) at the 70 th Annual Meeting of the American Academy of Neurology (AAN) in Los Angeles, April 21-27.

“While it’s been nearly one year since the FDA approved a second treatment option for ALS, there is still much to learn about this devastating disease,” said Jean Hubble, M.D., Vice President of Medical Affairs, MTPA. “In particular, we are eager to share findings from an analysis that identified clinically relevant signs and symptoms differentiating ALS patients from the general population up to five years prior to diagnosis. This is critical given it often takes up to 12 to 14 months for ALS patients to be accurately diagnosed.”

ALS data to be presented at AAN include:

ALS Presentation

  • Big Data Analytics for Early Diagnosis of Amyotrophic Lateral Sclerosis
    Abstract 459, Poster Session P4, Wednesday, April 25 from 11:30 a.m. – 7:00 p.m. PT

RADICAVA® (edaravone) Presentations

  • Hypersensitivity and Edaravone – Summary of Case Reports
    Abstract 465, Poster Session P3, Tuesday, April 24 from 11:30 a.m. – 7:00 p.m. PT
  • A Comparative Safety Analysis of the Edaravone Safety Profile Based on the ALS Japanese Severity Scale and Use over Time
    Abstract 438, Poster Session P4, Wednesday, April 25 from 11:30 a.m. – 7:00 p.m. PT
  • Post-hoc Analyses of an Edaravone Controlled Clinical Trial Suggest Similar Rates of Decline in King’s Amyotrophic Lateral Sclerosis (ALS) Clinical Staging across Subgroups
    Abstract 464, Poster Session P6, Friday, April 27 from 11:30 a.m. – 7:00 p.m. PT

About RADICAVA® (Edaravone)
The U.S. Food and Drug Administration (FDA) approved RADICAVA® (edaravone) on May 5, 2017 as a treatment for amyotrophic lateral sclerosis (ALS).1 In clinical trials, people given RADICAVA

experienced a 33 percent slower rate of decline in the loss of physical function, compared to placebo as measured by the ALS Functional Rating Scale-Revised (ALSFRS-R), a validated rating instrument for monitoring the progression of disability in people with ALS.1,2,3

RADICAVA is administered in 28-day cycles by intravenous infusion. It takes 60 minutes to receive each 60 mg dose. For the initial cycle, the treatment is infused daily for 14 consecutive days, followed by a two-week drug-free period. All cycles thereafter are infused daily for 10 days within a 14-day period, followed by a two-week drug-free period.1

Edaravone was discovered and developed for ALS by Mitsubishi Tanabe Pharma Corporation (MTPC) and commercialized in the U.S. by Mitsubishi Tanabe Pharma America, Inc. MTPC group companies began researching ALS in 2001 through an iterative clinical platform over a 13-year period. In 2015, edaravone was approved for use as a treatment for ALS in Japan and South Korea.

IMPORTANT SAFETY INFORMATION
Before you receive RADICAVA, tell your healthcare provider about all of your medical conditions, including if you:

  • have asthma.
  • are allergic to other medicines.
  • are pregnant or plan to become pregnant. It is not known if RADICAVA will harm your unborn baby.
  • are breastfeeding or plan to breastfeed. It is not known if RADICAVA passes into your breast milk. You and your healthcare provider should decide if you will receive RADICAVA or breastfeed.

Tell your healthcare provider about all the medicines you take, including prescription and over-the-counter medicines, vitamins, and herbal supplements.

What are the possible side effects of RADICAVA?

  • RADICAVA may cause serious side effects including hypersensitivity (allergic) reactions and sulfite allergic reactions.
  • Hypersensitivity reactions have happened in people receiving RADICAVA and can happen after your infusion is finished.
  • RADICAVA contains sodium bisulfite, a sulfite that may cause a type of allergic reaction that can be serious and life-threatening. Sodium bisulfite can also cause less severe asthma episodes in certain people. Sulfite sensitivity can happen more often in people who have asthma than in people who do not have asthma.
  • Tell your healthcare provider right away or go to the nearest emergency room if you have any of the following symptoms: hives; swelling of the lips, tongue, or face; fainting; breathing problems; wheezing; trouble swallowing; dizziness; itching; or an asthma attack (in people with asthma).
  • Your healthcare provider will monitor you during treatment to watch for signs and symptoms of all the serious side effects.

The most common side effects of RADICAVA include bruising (contusion), problems walking (gait disturbance), and headache.

These are not all the possible side effects of RADICAVA. Call your healthcare provider for medical advice about side effects. You may report side effects to Mitsubishi Tanabe Pharma America, Inc. at 1-888-292-0058 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.

For more information, including full Prescribing Information and Patient Information, please visit www.RADICAVA.com.

About Mitsubishi Tanabe Pharma America, Inc.
Based in Jersey City, N.J., Mitsubishi Tanabe Pharma America, Inc. (MTPA) is a wholly-owned subsidiary of Mitsubishi Tanabe Pharma Corporation’s (MTPC) 100 percent owned U.S. holding company, Mitsubishi Tanabe Pharma Holdings America, Inc. MTPA is dedicated to delivering innovative products that address the unmet medical needs of patients in North America. It was established by MTPC to commercialize approved pharmaceutical products in North America with plans to expand its product line through collaborations with partners. For more information, please visit or follow us on Twitter at www.mt-pharma-america.com or follow us on Twitter.

Overview of Mitsubishi Tanabe Pharma Corporation
Mitsubishi Tanabe Pharma, which was founded in 1678, has its headquarters in Doshomachi, Osaka, which is the birthplace of Japan’s pharmaceutical industry. With business centered on ethical pharmaceuticals, Mitsubishi Tanabe Pharma is a well-established company and has the longest history of any listed company in Japan. 4 In accordance with the corporate philosophy of “contributing to the healthier lives of people around the world through the creation of pharmaceuticals,” the Company formulated the key concept of Open Up the Future under the Medium-Term Management Plan 2016-2020. Through the discovery of drugs that address unmet medical needs, centered on its priority disease areas — autoimmune diseases, diabetes and kidney diseases, central nervous system diseases, and vaccines — Mitsubishi Tanabe Pharma will strive to contribute to the health of patients around the world. MTPC is the parent company of MTPA and the license holder of RADICAVA. For more information, go to http://www.mt-pharma.co.jp/.

Media inquiries:
Debbie Etchison
908-340-8578
Media_MTPA@mt-pharma-us.com


  1. RADICAVA® U.S. Prescribing Information. May 2017.
  2. Simon, N. G., Turner, M. R., Vucic, S., Al-Chalabi, A., Shefner, J., Lomen-Hoerth, C., & Kiernan, M. C. (2014). Quantifying Disease Progression in Amyotrophic Lateral Sclerosis. Annals of Neurology, 76(5), 643–657. http://dx.doi.org/10.1002/ana.24273</>.
  3. Abe K, Aoki M, Tsuji S, et al. (2017). Safety and efficacy of edaravone in well defined patients with amyotrophic lateral sclerosis: a randomised, double-blind, placebo-controlled trial. Lancet Neurology. 16(7), 505-512.http://dx.doi.org/10.1016/S1474-4422(17)30115-1.
  4. Research by TOKYO SHOKO RESEARCH, LTD.